The NM_000419.5:c.448A>G variant in ITGB3 is a missense variant predicted to cause substitution of methionine by valine at amino acid 150 (p.Met150Val). This variant has been detected in at least 3 probands with Glanzmann thrombasthenia. Two of these individuals were compound heterozygous for this variant and a pathogenic variant and one of those was confirmed to carry the variants in trans by parental testing (c.774_775del (phase not confirmed) and p.Asp145Tyr (phase confirmed)). An additional proband was reported to be homozygous for the variant (personal communication with Dr. Jose Rivera (Servicio de Hematologıa y Oncologıa Medica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonacion, Universidad de Murcia)) (PM3_Strong). At least one patient (Patient GT-1, PMID: 25539746) with this variant displayed mucocutaneous bleeding and impaired aggregation with all agonists except ristocetin, which is highly specific for Glanzmann thrombasthenia (PP4_Moderate). Additionally, αIIbβ3 surface expression was reduced to <25%), as measured by flow cytometry. However, ITGA2B and ITGB3 were not reported to be sequenced across all exons and intron/exon boundaries. The highest population minor allele frequency in gnomAD v2.1.1 is 0.00003266 (1/30616 alleles) in the South Asian population, which is lower than the ClinGen Platelet Disorders VCEP threshold (<0.0001) (PM2_Supporting). Furthermore, the computational predictor REVEL gives a score of 0.968, which is above the ClinGen Platelet Disorders VCEP threshold of >0.7 and predicts a damaging effect on function (PP3). In summary this variant meets criteria to be classified as likely pathogenic for autosomal recessive Glanzmann Thrombasthenia based on the ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP: PM2_Supporting, PM3_Strong, PP3, PP4_Moderate. (VCEP specifications version 2; date of approval 08/04/2022)